AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04912492 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol intoxication
Description: Men assigned to moderate alcohol dose condition (target BrAC .08%) with NIAAA approved alcohol administration procedures
Study NCT04912492 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No-Alcohol Placebo
Description: Men assigned to an no-alcohol placebo control condition.
Study NCT04912492 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No-Alcohol Placebo
Description: Men assigned to an no-alcohol placebo control condition.
Study NCT02933398 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic Assisted Nephrectomy
Description: Robotic (Davinci)
Study NCT02933398 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Assisted Nephrectomy
Description: Regular Laparoscopic Technique.
Study NCT06085664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5678
Description: Given by IV (vein)
Study NCT06085664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piflufolastat F18
Description: Given by IV (vein)
Study NCT05757791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: The full duration of therapy will be six-weeks. The route of administration will be oral. The starting dose of the medication will be 10mg daily for the first 14 days of the study, with a dose escalation to 25mg for the last 28 days of the study.
Study NCT06667232 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single-pulse stimulation
Description: Investigators use single-pulse electrical stimulations at 1Hz to elicit cortico-cortical evoked potentials
Study NCT06667232 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paired-pulse stimulation
Description: The repetitive delivery of pairs of stimulation pulses is DES patten with a 5-50 ms interval between each pulse, constitutes repetitive paired-pulse stimulation.
Study NCT06667232 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stepwise frequency stimulation
Description: Stepwise incremental stimulation ranging from 5 Hz to 145 Hz following a cyclic pattern.
Study NCT06667232 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Burst stimulation
Description: Burst stimulation pattern consisting of short bursts delivered once a second and an intraburst frequency of 50 Hz, 100 Hz, 150 Hz, 175 Hz and 200 Hz
Study NCT06610747 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Home-based Care Monitoring
Description: For participants in the home-based care group, home service appointments will be scheduled during the 'pro re nada' (PRN) treatment phase. Participants will receive a home self-administered visual acuity tester and a self-administered Home OCT to use at home every 4 weeks after the 5th injection through 48 weeks, and then as needed per the DME treatment regimen protocol provided in the protocol. The results of the visual acuity and OCT measurements will be transmitted to the clinician at the hospital. An online discussion between the clinician and the participant will be held. Reports will be sent to the participant after each visit. In the event that the study coordinator is unable to contact the participant, a total of three phone call attempts will be made. Any failure to keep an appointment will be communicated to the participant.
Study NCT06610747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept 2Mg/0.05Ml Inj,Oph
Description: Each eye will receive three to five q4week loading anti-VEGF injections of aflibercept (2-mg, EYLEA®) after enrollment to complete the initial loading phase of 5 doses. Each eye will then be treated according to the PRN treatment protocol described in the study protocol.
Study NCT06610747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept 2Mg/0.05Ml Inj,Oph
Description: Each eye will receive three to five q4week loading anti-VEGF injections of aflibercept (2-mg, EYLEA®) after enrollment to complete the initial loading phase of 5 doses. Each eye will then be treated according to the PRN treatment protocol described in the study protocol.
Study NCT06610747 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser Treatment
Description: Panretinal photocoagulation (PRP) may be administered if deemed necessary by the investigator, typically for high-risk proliferative diabetic retinopathy (PDR). However, individuals are not eligible for this study if it is expected that they will require PRP within 6 months at the time of enrollment. In general, PRP should not be given to study participants with less than high risk PDR. For previously untreated eyes exhibiting PDR with high-risk characteristics, PRP should be administered promptly, while it can be considered, although generally not recommended, for persons with non-high-risk PDR or severe non-PDR who are being monitored monthly in this protocol. Focal/grid laser typically should be withheld until sometime after the final visit.
Study NCT06610747 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser Treatment
Description: Panretinal photocoagulation (PRP) may be administered if deemed necessary by the investigator, typically for high-risk proliferative diabetic retinopathy (PDR). However, individuals are not eligible for this study if it is expected that they will require PRP within 6 months at the time of enrollment. In general, PRP should not be given to study participants with less than high risk PDR. For previously untreated eyes exhibiting PDR with high-risk characteristics, PRP should be administered promptly, while it can be considered, although generally not recommended, for persons with non-high-risk PDR or severe non-PDR who are being monitored monthly in this protocol. Focal/grid laser typically should be withheld until sometime after the final visit.
Study NCT06610747 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Hospital/clinic-based Care Monitoring
Description: For participants in the standard Hospital/clinic-based group, hospital service appointments will be scheduled during the \&amp;amp;amp;#39;pro re nada\&amp;amp;amp;#39; (PRN) treatment phase. Participants will be instructed to return to the clinic for hospital-based visual acuity examinations and standard OCT measurements every 4 weeks after the 5th injection through 48 weeks, and then as needed per the DME treatment regimen protocol provided in the protocol. A discussion between the clinician and the participant will be held in clinic. Reports will be sent to the participant after each visit. In the event that the study coordinator is unable to contact the participant, a total of three phone call attempts will be made. Any failure to keep an appointment will be communicated to the participant.
Study NCT06134076 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unfermented chickpea
Description: Frozen meals containing 100 g unfermented chickpeas
Study NCT06367946 — intervention group
Intervention type: PROCEDURE
Intervention: mechanical ventilation
Description: Mechanical ventilation is machine-delivered flow of gases to both oxygenate and ventilate a patient who is unable to maintain physiological gas exchange.
Study NCT06523049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorolanib Tablets
Description: Multi-targeted receptor tyrosine kinase inhibitor with potent inhibition of VEGFR2, KIT, PDGFR, FLT3 and RET, exerting anti-tumor effects mainly through inhibition of neovascularization.
Study NCT06523049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab Injection
Description: Recombinant human-derived immunoglobulin G (IgG4)-type anti-programmed cell death receptor-1 (PD-1) monoclonal antibody, by binding to PD-1 and blocking PD-1 binding to PD-L1 and PD-L2, disarms the immunosuppressive effect, activates T-cell function, and enhances T-cell immunosurveillance and killing ability against tumors to generate tumor immune response.
Study NCT05341778 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shoulder bridge
Description: The shoulder bridge is great for, strengthening your gluteal muscles, quadriceps, hamstrings, pelvic floor, abdominals and back muscles; most notably the tiny ones which control movement of each individual vertebrae and can weaken after episodes of back pain.
Study NCT05341778 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clam shell
Description: Scissors is an abdominal exercise that strengthens the transverse abdominals, helping flatten your belly and strengthen your entire core. Scissors is not only a core strength move, but it is also a great stretch for your hamstrings and your lower back.
Study NCT05341778 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clam shell
Description: Scissors is an abdominal exercise that strengthens the transverse abdominals, helping flatten your belly and strengthen your entire core. Scissors is not only a core strength move, but it is also a great stretch for your hamstrings and your lower back.
Study NCT05341778 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scissors
Description: Scissors is an abdominal exercise that strengthens the transverse abdominals, helping flatten your belly and strengthen your entire core. Scissors is not only a core strength move, but it is also a great stretch for your hamstrings and your lower back.
Study NCT05341778 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adductor squeeze
Description: Adductor Squeeze exercise The SQ exercise is an isometric hip adduction exercise with the player holding a ball between their knees.
Study NCT05341778 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adductor squeeze
Description: Adductor Squeeze exercise The SQ exercise is an isometric hip adduction exercise with the player holding a ball between their knees.
Study NCT05341778 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic clock supine
Description: The pelvic clock is a brilliant exercise to help achieve flexibility and strength in the lower back, pelvic floor, and core-in order to prevent pain and injury.
Study NCT06134076 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fermented chickpea
Description: Frozen meals containing 100 g fermented chickpeas
Study NCT06668961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI-B001
Description: Administration by intravenous infusion
Study NCT06668961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI-B003
Description: Administration by intravenous infusion
Study NCT06433752 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study NCT06672445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARO-ATXN2 Injection
Description: single dose of ARO-ATXN2 by intrathecal (IT) administration
Study NCT06672445 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: calculated volume to match active treatment by IT administration
Study NCT06616194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimegepant
Description: Rimegepant 75 mg orally disintegrating tablets
Study NCT06616194 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo oral disintegrating tablets
Study NCT06615986 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cardiosyn
Description: Two sachets by mouth daily. Each dose (sachet) is 8.1 grams. For 2 doses it will be 16.2 grams per person per day.
Study NCT05341778 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: urine hold and tummy tuck in
Description: During tummy tuck patients are able to strategically tighten and reinforce the muscles around the pelvic floor, urethra, and other structures. This increased strength and support greatly reduces stress urinary incontinence
Study NCT05341778 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bridging
Description: A bridge exercise isolates and strengthens your gluteus (butt) muscles - the gluteus maximus, medius and minimus - and hamstrings, which are the main muscles that make up the posterior chain. It is done by lying on your back with your knees bent, feet flat on the ground and at a comfortable distance from your butt.
Study NCT05341778 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Split table top
Description: To strengthen your abs, shoulders, arms and legs. The most important part of this move is to contract your abs fully before you start to lower your hips
Study NCT05341778 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrical muscle stimulation
Description: Electric stimulation works by mimicking the natural way by which the body exercises its muscles. The electrodes attached to the skin deliver impulses that make the muscles contract. It is beneficial in increasing the patient's range of motion and improves the circulation of the body.
Study NCT05341778 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical muscle stimulation
Description: Electric stimulation works by mimicking the natural way by which the body exercises its muscles. The electrodes attached to the skin deliver impulses that make the muscles contract. It is beneficial in increasing the patient's range of motion and improves the circulation of the body.
Study NCT06173388 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured exercise training program + The swallow resistance exercise program.
Description: Structured exercise training program + The swallow resistance exercise program.
Study NCT06173388 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Only the swallow resistance exercise program.
Description: Only the swallow resistance exercise program.
Study NCT06173388 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Only the swallow resistance exercise program.
Description: Only the swallow resistance exercise program.
Study NCT06324643 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sensory motor integration training
Description: one group treated by strengthening exercises , stretching ,and occupational therapy and other group treated by strengthening exercises , stretching ,and occupational therapy and sensory motor integration training
Study NCT05290948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravitreal injection of bevacizumab with acetazolamide tablets
Description: intravitreal injection of bevacizumab with acetazolamide tablets
Study NCT05290948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravitreal injection of bevacizumab
Description: intravitreal injection of bevacizumab
Study NCT04964661 — intervention group
Intervention type: OTHER
Intervention: Medical Imaging
Description: MRI imaging
Study NCT04871152 — intervention group
Intervention type: DRUG
Intervention: OnabotulinumtoxinA
Description: To compare the effectiveness of triptans before and after initiation of treatment with OnabotuliumtoxinA.
Study NCT05987826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furmonertinib
Description: Furmonertinib 80mg QD oral 8 weeks.
Study NCT05556980 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: totally laparoscopic distal gastrectomy
Description: all the surgical procedure would be finished under laparoscopy
Study NCT04633226 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114
Description: 15-valent pneumococcal conjugate vaccine (PCV) containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) present in Prevnar 13™ plus 2 additional serotypes (22F, 33F) in each 0.5 mL sterile suspension for intramuscular injection.
Study NCT05717725 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed-field ablation
Description: Patients will receive catheter ablation, i.e. pulmonary vein isolation by means of pulsed-field energy
Study NCT05717725 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: Patients will receive sham procedure, no ablation.
Study NCT05036798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Chemotherapy regimen:~Gemcitabine 1g/m2 Oxaliplatin 100mg/m, D1, q3W2 Tislelizumab 200mg D1 Q3w Lenvatinib 4mg Po QD
Study NCT06589414 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Patient care according to the DAMeGe protocol (organisation of a summary consultation with the GP)
Description: A summary consultation with the patient's general practitioner (GP) will take place within 15 days of the consultation to announce the cancer diagnosis. This patient-general practitioner consultation will complement the initial consultation.~At the end of the summary consultation, the patient's satisfaction and that of the GP will be assessed using satisfaction questionnaires.~In addition, patients will be asked to complete a patient diary for the duration of their participation in the study (6 months), in order to record the dates of consultations with the GP and the dates of consultations and/or hospitalisations at the referral care centre.
Study NCT05347485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilta-cel
Description: Cilta-cel will be administered as an IV infusion.
Study NCT05347485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lymphodepleting Therapy (Cyclophosphamide and Fludarabine)
Description: Lymphodepleting therapy (cyclophosphamide and fludarabine) will be administered intravenously.
Study NCT06676540 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodevelopmental Therapy (NDT) and Eccentric Exercise Training Group (NDT+EE)
Description: Including Functional Eccentric Exercises Applied to Individuals with Cerebral Palsy
Study NCT06676540 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurodevelopmental Therapy (NDT)
Description: This application includes rehabilitation methods frequently used in pediatric rehabilitation.
Study NCT06676540 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodevelopmental Therapy (NDT)
Description: This application includes rehabilitation methods frequently used in pediatric rehabilitation.
Study NCT06362993 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bundling
Description: Education on and screening for diabetes and hypertension offered together with education and screening for breast cancer.
Study NCT06362993 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MEGH
Description: Education on breast cancer and discussion sessions to male partners to change men's gender attitudes and behaviors.
Study NCT05398445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocatinlimab
Description: Participants will receive Rocatinlimab subcutaneously.
Study NCT05398445 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a placebo subcutaneously.
Study NCT05211050 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levcromakalim
Description: 20 min infusion of 1 mg Levcromakalim followed by either sumatriptan or placebo.
Study NCT05211050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levcromakalim
Description: 20 min infusion of 1 mg Levcromakalim followed by either sumatriptan or placebo.
Study NCT05211050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sumatriptan
Description: 10 min infusion of 4 mg sumatriptan.
Study NCT05211050 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 10 min infusion of isotonic saline (placebo).
Study NCT04661137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor 60 MG
Description: Selinexor 60 mg PO on days 1, 8 and 15
Study NCT04661137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor 80 MG
Description: Selinexor 80 mg PO on days 1, 8 and 15
Study NCT04661137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor 100 MG
Description: Selinexor 100 mg PO on days 1, 8, 15 and 22
Study NCT04661137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: 56 mg/m2 IV on days 1, 8 and 15
Study NCT04661137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: 4 mg PO daily for 21 days
Study NCT04661137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: 16 mg/kg IV days 1, 8, 15 and 22 for cycles 1-2; days 1 and 15 for cycles 3-6; day 1 for cycle 7 and on
Study NCT04661137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg if ≥ 75 years old and 40 mg if \< 75 years old on days 1, 8, 15 and 22
Study NCT05694806 — intervention group
Intervention type: OTHER
Intervention: analysis of thoracic scans
Description: analysis of thoracic scans realised in standard care
Study NCT04322669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pidotimod
Description: Participants will be randomized in ratio of 1:1 to receive Pidotimod 400 milligrams (mg), once daily (no infection present) or twice daily (infection present) orally up to Day 60 during the double-blind treatment period.
Study NCT04322669 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be randomized in ratio of 1:1 to receive placebo matched to Pidotimod, once daily (no infection present) or twice daily (infection present) orally up to Day 60 during the double-blind treatment period.
Study NCT05867134 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Removal of postoperative lifting restrictions
Description: Patients will be randomized into one of two groups: a control group told to practice standard of care at Eastern Colorado VA with return to activity precautions (6 weeks for open surgery, 2 weeks for minimally invasive surgery) and a treatment group told to return to activity as tolerated/comfortable and stop activity if pain present.